Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics

Executive Summary

The US FDA cleared Sanofi/Regeneron's IL-4/IL-13 inhibitor for moderate-to-severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, a broader label than AstraZeneca's Fasenra, GSK's Nucala and Teva's Cinqair.

You may also be interested in...



Dupixent Gets Room To Grow With New Indication In Chronic Rhinosinusitis

The new indication represents the third one for Sanofi/Regeneron's IL-4/IL-13 inhibitor, after atopic dermatitis and moderate to severe asthma.

Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene

The latest drug development news and highlights from our US FDA Performance Tracker.

Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent

Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel